[Skip to Content]
[Skip to Content Landing]
Views 571
Citations 0
Comment & Response
September 3, 2020

Demystifying the Role of Tumor Mutational Burden for Immunotherapy Selection

Author Affiliations
  • 1Foundation Medicine Inc, Cambridge, Massachusetts
JAMA Oncol. Published online September 3, 2020. doi:10.1001/jamaoncol.2020.3386

To the Editor In their Invited Commentary, Waqar and Govindan1 describe some of the confounding factors that may have influenced the outcomes of 2 pivotal studies—the Checkmate 227 study (NCT02453282) and the MYSTIC study (NCT02477826)—that evaluated the ability of tumor mutational burden (TMB) to enrich survival in patients treated with immunotherapy vs standard of care. While important, their commentary falls short of fully characterizing the current landscape of TMB as an immunotherapy-guided biomarker.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words